# FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

> **NCT04768972** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ION363
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04768972
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-14
- **Primary completion:** 2026-06
- **Final completion:** 2028-03
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768972, "FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04768972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*